Results 71 to 80 of about 9,532 (171)

Chemoimmunotherapy‐associated CD20 (MS4A1) resistance mutations in Waldenström macroglobulinemia: Epitope disruption independent of expression with implications for CD20‐directed cellular therapies

HemaSphere, Volume 10, Issue 10, October 2026.
Alberto Guijosa, Nickolas Tsakmaklis, Sirano Dhe‐Paganon, Filip Garbicz, Ruben Carrasco, John Hatcher, Andres Ramirez‐Gamero, Dominic Pizzarella, Amanda Kofides, Shirong Liu, Hao Sun, Xia Liu, María L. Guerrera, Andrew R. Branagan, Gottfried von Keudell, Shayna R. Sarosiek, Jorge J. Castillo, Zachary R. Hunter, Steven P. Treon   +18 more
wiley   +1 more source

Pomalidomide in the treatment of multiple myeloma: design, development and place in therapy

, 2017
Rafael Ríos-Tamayo,1–4 Agustín Martín-García,5,6 Carolina Alarcón-Payer,5 Dolores Sánchez-Rodríguez,1,7 Ana María del Valle Díaz de la Guardia,5 Carlos Gustavo García Collado,5 ...
Alarcón-Payer C, Jurado Chacón M, Cabeza Barrera J, García Collado CG, Rios-Tamayo R, Guardia AM, Jiménez Morales A, Sánchez-Rodríguez D, Martín-García A   +8 more
core  

A Phase I, open-label, randomized, crossover study in healthy subjects to evaluate the bioavailability of, and the food effect on, a pomalidomide oral liquid suspension

Clinical Pharmacology: Advances and Applications, 2018
Yan Li,1 Liangang Liu,2 Lian Huang,3 Xiaomin Wang,4 Matthew Hoffmann,4 Josephine Reyes,1 Maria Palmisano,1 Simon Zhou1 1Translational Development and Clinical Pharmacology, 2Biometrics and Data Operations, 3Pharmaceutical Science Drug Product Development,
Li Y, Liu L, Huang L, Wang X, Hoffmann M, Reyes J, Palmisano M, Zhou S   +7 more
doaj  

Targeting Ikaros and Aiolos with pomalidomide fails to reactivate or induce apoptosis of the latent HIV reservoir

Journal of Virology
HIV persists in people living with HIV (PLHIV) on antiretroviral therapy (ART) in long-lived and proliferating latently infected CD4+ T cells that selectively express pro-survival proteins, including the zinc finger proteins, Ikaros and Aiolos.
Rachel D. Pascoe, Youry Kim, Ajantha Rhodes, Jesslyn Ong, Carolin Tumpach, Celine Gubser, J. Judy Chang, James H. McMahon, Sharon R. Lewin, Thomas A. Rasmussen   +9 more
doaj   +1 more source

Pomalidomide in Combination with Low-Dose Dexamethasone as the Treatment of “Double Refractory” Multiple Myeloma

Клиническая онкогематология, 2017
Background. The development of radical therapy for multiple myeloma (MM) is still a pressing problem. This progressive disease requires repeated courses of therapy using drugs without cross-resistance.
Aleksei Vladilenovich Petrov, D. V. Motorin, O. S. Pokrovskaya, E. S. Urnova, M. V. Nareiko, D. V. Babenetskaya, Yu. A. Alekseeva, L. L. Girshova, L. P. Mendeleeva, A. Yu. Zaritskii   +9 more
doaj   +1 more source

The Role of Pomalidomide-Based Epigenetic Effect on DNMT Genes Expression in Myeloma Cell Line

Acta Medica Iranica, 2018
Multiple myeloma (MM) is clonal B-cell malignancy characterized by the progressive proliferation of malignant plasma cells and accumulation of monoclonal immunoglobulin (M-spike) in blood and urine.
Ali Dehghani Fard, Saeid Kaviani, Mehrdad Noruzinia, Masoud Soleimani, Abbas Hajifathali   +4 more
doaj  

Pomalidomide increases immune surface marker expression and immune recognition of oncovirus-infected cells

OncoImmunology, 2019
Most chronic viruses evade T-cell and natural killer (NK) immunity through downregulation of immune surface markers. Previously we showed that Pomalidomide (Pom) increases surface expression of major histocompatibility complex class I (MHC-I) in Kaposi ...
David A. Davis, Prabha Shrestha, Ashley I. Aisabor, Alexandra Stream, Veronica Galli, Cynthia A. Pise-Masison, Takanobu Tagawa, Joseph M. Ziegelbauer, Genoveffa Franchini, Robert Yarchoan   +9 more
doaj   +1 more source

Pomalidomide: A Review in Relapsed and Refractory Multiple Myeloma

, 2018
Compliance with Ethical StandardsFunding: The preparation of this review was not supported by any external funding.Conflicts of interest: Sheridan Hoy is a salaried employee of Adis/Springer, is responsible for the article content and declares no ...
Sheridan M. Hoy (4897468)
core   +2 more sources

Randomized Phase 3 study of pomalidomide cyclophosphamide dexamethasone versus pomalidomide dexamethasone in relapse or refractory myeloma: an Asian Myeloma Network study (AMN003)

Blood Cancer Journal
Pomalidomide has been shown to improve survival in patients with relapsed/refractory myeloma (RRMM). However, the optimal pomalidomide-based combinations in RRMM are not known.
Jin Seok Kim, Yang Song, Wei-Ying Jen, C. S. Chim, Je-Jung Lee, Sung-Soo Yoon, Soo Chin Ng, Gin Gin Gan, Hiroshi Handa, Jae Hoon Lee, Kihyun Kim, Shigeki Ito, Jeffrey Shang-Yi Huang, Chang Ki Min, Melissa Ooi Gaik Ming, Sanjay de Mel, Cinnie Soekojo, Xinhua Li, Neha Awasthi, Yogesh Pokharkar, Brian GM Durie, Wee-Joo Chng   +21 more
doaj   +1 more source

Pomalidomide improves the effectiveness of CAR-T treatment in the relapsed and refractory multiple myeloma or B-cell leukemia/lymphoma with extramedullary disease

Blood Science
Relapsed and refractory multiple myeloma (RRMM) and B-cell leukemia/lymphoma with extramedullary disease (EMD) have poor prognosis and high mortality, lack of effective therapeutic approaches. We reported for the first time that 6 patients with malignant
Jie Zhao, Hui Yang, Junnan Ge, Linyu Li, Qiong Yao, Shaolong He, Qiujuan Zhu, Ruiui Ren, Chunrui Li, Liangming Ma, Weiwei Tian, Jia Wei   +11 more
doaj   +1 more source